European Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading

MT Newswires Live
Yesterday

European equities traded in the US as American depositary receipts were trending higher late Wednesday morning, rising 0.50% to 1,960.43 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and semiconductor company Sequans Communications (SQNS), which rose 4% and 3.6% respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and lender ING Group (ING), which were up 3.5% and 2.9% respectively.

The decliners from continental Europe were led by internet browser company Opera (OPRA) and petroleum refiner Equinor (EQNR), which dropped 2.3% and 1.5% respectively. They were followed by telecommunications companies Nokia (NOK) and Ericsson (ERIC), which lost 0.8% and 0.7% respectively.

The gainers from the UK were led by hospitality company InterContinental Hotels Group (IHG) and biopharmaceutical company Bicycle Therapeutics (BCYC), which advanced 4.1% and 3.1% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and mining company BHP Group (BHP), which increased 1.5% and 1.4% respectively.

The decliners from the UK and Ireland were led by educational publisher Pearson (PSO) and biotech firm Trinity Biotech (TRIB), which fell 2.8% and 2.5% respectively. They were followed by communications company WPP (WPP) and biopharmaceutical company Mereo BioPharma Group (MREO), which were down 2.4% and 2.3% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10